Payment overview · 2025
General Payments
$1,153.04
69 reported records · 8 companies
Healthcare provider profile · identity verified
Stephen Holmes, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SPRINGFIELD, MO · NPI 1831132240
Verified facts
What the public records show
CMS Open Payments records show Stephen Holmes, MD received $1,153.04 in general payments during 2025 across 69 reported records.
Lilly USA, LLC accounted for 18.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Farxiga, Mounjaro, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 235 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $212.84 | 18.5% | 15 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $209.96 | 18.2% | 13 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $209.76 | 18.2% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $153.02 | 13.3% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $148.82 | 12.9% | 9 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $135.92 | 11.8% | 6 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $65.39 | 5.7% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.33 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,153.04 | 69 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $209.76 | 9 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $178.60 | 13 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $148.82 | 9 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $135.92 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $115.08 | 9 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $112.54 | 10 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $92.61 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $80.05 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $70.52 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $68.47 | 4 | 2025 |
Source payment records
|
|||||
| FABRAZYME Normalized: fabrazyme |
Biological | GENZYME CORPORATION | $42.30 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $40.48 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $40.48 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $34.24 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 85 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 235 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 93 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 80 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 92 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
93 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
85 | 85 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
29 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
96 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
80 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
92 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
102 | 102 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
235 | 54 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 838 | 216 |
| Atorvastatin Calcium | Atorvastatin Calcium | 830 | 226 |
| Levothyroxine Sodium | Levothyroxine Sodium | 773 | 178 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 689 | 200 |
| Lisinopril | Lisinopril | 593 | 156 |
| Gabapentin | Gabapentin | 592 | 125 |
| Losartan Potassium | Losartan Potassium | 519 | 142 |
| Potassium Chloride | Potassium Chloride | 387 | 96 |
| Omeprazole | Omeprazole | 348 | 92 |
| Pantoprazole Sodium | Pantoprazole Sodium | 313 | 83 |
| Carvedilol | Carvedilol | 308 | 73 |
| Duloxetine Hcl | Duloxetine Hcl | 308 | 75 |
| Metformin Hcl | Metformin Hcl | 296 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 249 | 76 |
| Metoprolol Tartrate | Metoprolol Tartrate | 248 | 74 |
| Eliquis | Apixaban | 235 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 233 | 68 |
| Pravastatin Sodium | Pravastatin Sodium | 227 | 60 |
| Chlorthalidone | Chlorthalidone | 219 | 64 |
| Trazodone Hcl | Trazodone Hcl | 210 | 51 |
| Famotidine | Famotidine | 198 | 46 |
| Metformin Hcl Er | Metformin Hcl | 195 | 56 |
| Simvastatin | Simvastatin | 195 | 54 |
| Fluticasone Propionate | Fluticasone Propionate | 190 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 188 | 52 |
| Sertraline Hcl | Sertraline Hcl | 183 | 46 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 179 | 41 |
| Tramadol Hcl | Tramadol Hcl | 164 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 161 | 36 |
| Spironolactone | Spironolactone | 149 | 44 |
| Montelukast Sodium | Montelukast Sodium | 145 | 30 |
| Furosemide | Furosemide | 142 | 37 |
| Allopurinol | Allopurinol | 140 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 140 | 47 |
| Meloxicam | Meloxicam | 137 | 38 |
| Alendronate Sodium | Alendronate Sodium | 136 | 44 |
| Azelastine Hcl | Azelastine Hcl | 133 | 39 |
| Buspirone Hcl | Buspirone Hcl | 115 | 25 |
| Valsartan | Valsartan | 113 | 31 |
| Finasteride | Finasteride | 107 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 106 | 27 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 102 | 102 |
| Mirtazapine | Mirtazapine | 100 | 25 |
| Jardiance | Empagliflozin | 96 | 20 |
| Farxiga | Dapagliflozin Propanediol | 93 | 21 |
| Ozempic | Semaglutide | 92 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 91 | 42 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 90 | 16 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 85 | 85 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 82 | 19 |
| Mounjaro | Tirzepatide | 80 | 18 |
| Pregabalin | Pregabalin | 77 | 17 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 76 | 76 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 15 |
| Atenolol | Atenolol | 75 | 21 |
| Bupropion Hcl Sr | Bupropion Hcl | 75 | 21 |
| Ezetimibe | Ezetimibe | 68 | 12 |
| Benazepril Hcl | Benazepril Hcl | 66 | 17 |
| Lorazepam | Lorazepam | 59 | 13 |
| Donepezil Hcl | Donepezil Hcl | 57 | 14 |
| Warfarin Sodium | Warfarin Sodium | 56 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 53 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | 11 |
| Prednisone | Prednisone | 52 | 35 |
| Lovastatin | Lovastatin | 51 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 43 |
| Ramipril | Ramipril | 49 | 14 |
| Glimepiride | Glimepiride | 46 | 14 |
| Celecoxib | Celecoxib | 42 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 41 | 11 |
| Synthroid | Levothyroxine Sodium | 41 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 40 | suppressed |
| Estradiol | Estradiol | 39 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | 12 |
| Venlafaxine Hcl | Venlafaxine Hcl | 39 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 30 |
| Alprazolam | Alprazolam | 33 | suppressed |
| Irbesartan | Irbesartan | 33 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 31 |
| Rybelsus | Semaglutide | 32 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 29 | 23 |
| Valacyclovir | Valacyclovir Hcl | 29 | 14 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 28 | 14 |
| Bumetanide | Bumetanide | 27 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 27 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 18 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Indapamide | Indapamide | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 21 |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Repatha Syringe | Evolocumab | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,153.04 · 69 records | Lilly USA, LLC | AIRSUPRA, AREXVY, BREZTRI, Dexcom G6 Transmitter, ELIQUIS, FABRAZYME, FARXIGA, FREESTYLE LIBRE, KISUNLA, MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error